1 2 3	Clinical Practice Guideline:	Techniques and Procedures Not Widely Supported as Evidence-Based
4	Date of Implementation:	July 21, 2010
5 6 7	Product:	Specialty

8

9 GUIDELINES

American Specialty Health – Specialty (ASH) clinical committees have established that a 10 technique and/or procedure that is unproven, poses a significant health and safety risk 11 and/or is scientifically implausible requires specific informed consent from members. Such 12 consent must include a signed written attestation that the patient understands the current 13 state of the evidence for, and the possible risks associated with, a technique or procedure 14 prior to receiving it. Information from associated Clinical Practice Guidelines (CPGs) may 15 be included as appropriate. The list of techniques and/or procedures in this guideline is not 16 exhaustive; included are those techniques and procedures that have been specifically 17 evaluated by ASH clinical committees and determined to pose a significant health and 18 safety risk, to be scientifically implausible, or to be unproven based on the current state of 19 20 the literature.

21

22 Prior to receiving it, patients must be informed verbally and in writing if any procedure or treatment technique is considered experimental/investigational or unproven, poses a 23 significant health and safety risk, and/or is scientifically implausible. If the patient decides 24 to receive this procedure or treatment, they must sign a Member Billing Acknowledgment 25 Form (for Medicare use Advance Beneficiary Notice of Non-Coverage form) indicating 26 they understand they are assuming financial responsibility for any service-related fees. 27 28 Further, the patient must sign an attestation indicating that they understand what is known and unknown about, and the possible risks associated with such techniques prior to 29 receiving these services. All procedures, including those considered here, must be 30 31 documented in the patients' medical record. Finally. prior to using 32 experimental/investigational or unproven procedures, those that pose a significant health and safety risk, and/or those considered scientifically implausible, it is incumbent on the 33 34 practitioner to confirm that their professional liability insurance covers the use of these techniques or procedures in the event of an adverse outcome. 35 36

37 **PROCESS AND DEFINITIONS**

The ASH clinical procedure assessment process evaluates diagnostic and therapeutic procedures against professionally recognized standards of practice, current scientific evidence, and consensus of appropriate experts. The recommendations of the consensus panel are considered by ASH clinical committees when developing criteria, definitions,

Page 1 of 7

1 2	and processes to support clinical decision-making within ASH's clinical management system.
3	
4 5	When developing, reviewing, and approving clinical policy, ASH peer-review committees consider whether the technique/procedure:
6	• Is evidence-based with support from clinically relevant scientific information
7	which:
8	• Can be used to inform the diagnosis or treatment of a patient.
9	 Meets industry standard research quality criteria.
10	• Is adopted as credible by an ASH clinical peer review committee.
11	• Has been published in an acceptable peer-reviewed clinical science
12	resource.
13	• Is established as clinically effective/established as having diagnostic utility by:
14 15	• Scientific information published in an acceptable peer-reviewed clinical science resource.
16	• The consensus opinion of the Evidence Evaluation Committee (EEC) when
17	available.
18	• Is professionally recognized by:
19	• Inclusion in the educational standards accepted by the majority of the
20	professions' educational institutions.
21	• Wide acceptance and use of the practice.
22	• Recommendations for use made by healthcare practitioners practicing in
23	the relevant clinical area.
24	• Poses a health and safety risk.
25	• Is plausible or implausible.
26	• A belief, theory, or mechanism of health and disease that can be explained
27	within the existing framework of scientific methods, reasoning and
28	available knowledge is considered plausible.
29	• A treatment intervention or diagnostic procedure that requires the existence
30	of forces, mechanisms, or biological processes that are not known to exist
31	within the current framework of scientific methods, reasoning and
32	available knowledge is considered implausible.
33	• Is approved by the appropriate federal regulatory agency and being used for the
34	purpose defined in that approval (unless it is considered an off-label use or
35	otherwise meets the generally accepted standards of medical practice).
36	• This criterion applies to drugs, biological products, devices, and any other
37	product or procedure that must have final approval to market from the U.S.
38	Food and Drug Administration (FDA) or any other federal government
39	body with authority to regulate the technology. However, approval by the
40	FDA or other federal regulatory agency does not imply that the technology
41	is automatically considered by ASH as medically necessary or the accepted
42	standard of care.

Page 2 of 7

1 Other Considerations

- 2 **Substitution harm (indirect harm):** Compromised clinical outcomes caused by:
- Utilizing a specific diagnostic or therapeutic procedure when the safety, clinical effectiveness, or diagnostic utility is either unknown or is known to be unsafe, ineffective, or of no diagnostic utility, *instead of* a diagnostic or therapeutic procedure known to be safe, be clinically effective, or to have diagnostic utility.
- The utilization of a diagnostic or therapeutic procedure that is substantially less
 effective or safe than another procedure with established safety, and clinical
 effectiveness or utility.
- 10

Labeling effects (non-specific harm): The harm that results from identifying in a patient

- 12 a condition or a finding that is not clinically valid.
- 13

Technique / Procedure*
ABO Blood Typing for Diagnosis and/or Treatment
Actra-Rx
Acutonics/Sonotonics
Addictionology
Advanced Biostructural Correction (ABC)
Antineoplastons
Antioxidant Function Testing (e.g., Spectrox TM)
Apitherapy
Applied Kinesiology (AK)
Aromatherapy
Ashiatsu Oriental Bar Therapy (See the Ashiatsu Oriental Bar Therapy (CPG 82 –S)
clinical practice guideline)
Aura Healing
Auto-Urine Therapy (or Urine Therapy)
Autogenous Lymphocytic Factor
Ayurvedic Medicine (Herbal Therapies)
Bach Flower Remedies
Bee Sting Therapy
Bio Energetic Synchronization Technique (BEST)
Bio-Cranial Therapy (BCT)
Bioenergetic Sensitivity and Enzyme Therapy (BioSET)
Biofield CanCell (Entelev) Therapy
Bio-Geometric Integration (BGI)
Biological Terrain Assessment (BTA)
BioMagnetic Therapy
Bio-oxidative Therapy (e.g., ozone, hydrogen peroxide, singlet oxygen)

CPG 133 Revision 20 – S Techniques and Procedures Not Widely Supported as Evidence-Based **Revised – June 19, 2025** To CQT for review 05/12/2025 CQT reviewed 05/12/2025 To QIC for review and approval 06/03/2025 QIC reviewed and approved 06/03/2025 To QOC for review and approval 06/19/2025

QOC reviewed and approved 06/19/2025

Page 3 of 7

Bovine Cartilage Products

Carbon Dioxide Therapy

Cari-Loder Regimen (lofepramine plus phenylalanine with B12)

Cellular Therapy

Chelation Therapy for Atherosclerosis (See the *IV Chelation Therapy (CPG 104 –S*) clinical practice guideline)

Clinical Kinesiology

Coley's Toxin

Colonic Irrigation

Colorpuncture

Concept Therapy

Contact Reflex Analysis (CRA)

COVID-19 (any non-FDA-approved therapy aimed at prevention or treatment of COVID-19 or associated illnesses.)

CranioSacral Therapy (See the *CranioSacral Therapy (CST) (CPG 35 –S)* clinical practice guideline)

Cupping (See the *Instrument-Assisted Soft Tissue Mobilization (CPG 89-S)* clinical practice guideline)

Directional Non-Force Technique (DNFT)

Dry Hydrotherapy/Aquamassage/Hydromassage

Dry Needling (not acupuncture) (See the *Dry Needling (CPG 178 – S)* clinical practice guideline)

Ear Candling

Electro-Meridian Diagnosis Category:

- BioMeridian (Meridian Stress Assessment [MSA] Machine)
- ElectroAcupuncture by Voll (EAV)
- Electrodermal Screening Test (EDST)
- Ryodoraku/Electro Meridian Imaging (EMI)
- Vega testing

Essiac

Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions

Fasting

Force Recording and Analysis System (FRAS)

Fresh Cell Therapy

Functional Intracellular Analysis, also known as:

- Essential Metabolic Analysis;
- Intracellular Micronutrient Analysis;
- Leukocyte Nutrient Analysis; and/or Micronutrient Analysis

Gemstone and/or Crystal Therapy

CPG 133 Revision 20 – S

Techniques and Procedures Not Widely Supported as Evidence-Based **Revised – June 19, 2025** To CQT for review 05/12/2025 CQT reviewed 05/12/2025 To QIC for review and approval 06/03/2025 QIC reviewed and approval 06/03/2025 To QOC for review and approval 06/19/2025 QOC reviewed and approved 06/19/2025 Page 4 of 7

Hair Mineral Analysis (See the *Hair Mineral Analysis – Nutritional Management* (*CPG 103 - S*) clinical practice guideline)

Holistic Kinesiology

Immuno-Augmentive Therapy (IAT)

Infrasonic/Infrasonic Therapy

Insulin Potentiation Therapy

Intensive Model of Therapy (See the *Intensive Model of Therapy (CPG 286 – S)* clinical practice guideline)

Intracellular Nutrient Analysis

Intravenous venous Micronutrient Therapy (Myers' Cocktail)

Intravenous Nutrient Therapy

Inversion Therapy (See the *Inversion Therapy* (*CPG* 107 - S) clinical practice guideline)

Iridology

Iscador (Mistletoe)

Jaffe-Mellor Technique (JMT)

Kelley/Gonzalez Therapy

Laetrile

Laser Therapy (See the Laser Therapy (CPG 30 - S) clinical practice guideline)

Live Blood Cell Analysis

Manual Muscle Testing - to evaluate Internal/Visceral disorders

Manual Muscle Testing - to evaluate Psychological disorders

Markerless 3D kinematic and kinetic motion analysis and report, Comprehensive full body computer-based

Matrix Repatterning / Energetics

MEDEK Therapy (See the *MEDEK Therapy* (*CPG 276 –S*) clinical practice guideline) Medicinal Mushrooms

Megavitamin Therapy (Orthomolecular Medicine)

Mesotherapy

Micronutrient Panel Testing

Mistletoe (Iscador)

MTH-68/H Vaccine

Moxibustion – Direct (See the *Moxibustion CPG 48 – S*) clinical practice guideline) Nambudripad's Allergy Elimination Technique (NAET®)

Needle Implants (Intradermal Needles, Ear tacks, etc.) (See the *Intradermal Needles* and Ear Tacks (CPG 50 – S) clinical practice guideline)

Network Spinal Analysis (NSA)

Neural Therapy

Neuro Emotional Technique (NET)

CPG 133 Revision 20 – S

Techniques and Procedures Not Widely Supported as Evidence-Based **Revised – June 19, 2025** To CQT for review 05/12/2025 CQT reviewed 05/12/2025 To QIC for review and approval 06/03/2025 QIC reviewed and approval 06/03/2025 To QOC for review and approval 06/19/2025 QOC reviewed and approved 06/19/2025 Page 5 of 7

Neuro Organizational Technique (NOT)

Neuro Vascular Dynamics (NVD)

Neurogenx

Neuro-Linguistic Programming (NLP)

Neurolink

New-Stim Bio-Kinetics

Non-invasive Interactive Neurostimulation (e.g., InterX®- all types) (See the *Non-invasive Interactive Neurostimulation (InterX®) (CPG 277- S)* clinical practice guideline)

Organ/Visceral Manipulation

Organic Acid Testing

Ortho-Bionomy

Peat Therapies

• Balneotherapy

Phage Therapy

Polarity Therapy (Energetic Healing)

(Poon's) Chinese Blood Cleaning

Prolonged Fasting Programs

Purging

Prolotherapy (See the *Prolotherapy* (*CPG* 94 - S) clinical practice guideline)

Radionics

Reflexology

Regenerative Medicine (Stem Cell Treatments, Platelet-rich Plasma Injections)

Regenokine Therapy

Reiki

Rife Therapy/Rife Machine

Sacro-Occipital Technique (SOT)TM (See the *Sacro Occipital Technique (SOT) (CPG* 96 - S) clinical practice guideline)

Sarapin Injections (See the *Acupuncture Point Injection Therapy (APIT) (CPG 118 – S)* clinical practice guideline)

Shark Cartilage Products

SonoKinesthesia Treatment

Surrogate Testing

Therapeutic Touch Therapy (See the *Therapeutic Touch Therapy* ($CPG \ 106 - S$) clinical practice guideline)

Telomere Testing

Therapeutic Eurythmy

Thought Field Therapy (TFT)

Callahan Technique Training

CPG 133 Revision 20 – S

Techniques and Procedures Not Widely Supported as Evidence-Based **Revised – June 19, 2025** To CQT for review 05/12/2025 CQT reviewed 05/12/2025 To QIC for review and approval 06/03/2025 QIC reviewed and approved 06/03/2025 To QOC for review and approval 06/19/2025 QOC reviewed and approved 06/19/2025 Page 6 of 7

Threshold Electrical Stimulation

Toftness Radiation Detector

Total Body Modification (TBM)

Traumeel Preparation

Trichuris Suis Ova Therapy

Urinary Organic Acids Profiling

Vascular Endothelial Cells (VEC) Therapy

Vector Point Cranial Therapy

Vibrational Essences

Videonystagmography (VNG) (See the *Vestibular Rehabilitation* (*CPG* 173 - S) clinical practice guideline)

Virtual Reality – Motor-cognitive, semi-immersive virtual reality-facilitated gait training

Virtual reality technology to assist therapy

Webster Technique (See the *Webster Technique* (CPG 99 - S) clinical practice guideline)

Whitcomb Technique

Wurn Technique (Clear Passage Technique)

714-X or 714X

1 *Note: This is not an exhaustive list of all techniques and/or procedures that are not evidence-based practice.

2 All techniques and/or procedures utilized should be evaluated by the practitioner against the current accepted

3 scientifically valid clinical literature and the above defined criteria.